The bacterial component LPS dramatically alters the immuno-phenotype of glioma cells and GSCs via TLR4 signaling, which enhances glioma immunogenicity and elicits antitumoral immunity, thereby providing a new perspective for glioma immunotherapy. The gene discussed is TLR4; the disease is glioma.